The paper lacks clarity on why significant discrepancies in off-label prescription rates (32.9% vs. 18.4%) between pharmacists and physicians were observed, raising concerns about methodological consistency. The small sample size (169 patients) limits the generalizability of findings, particularly for broader pediatric populations. Additionally, the absence of patient and family perspectives, despite their importance in off-label prescribing, undermines the study’s comprehensiveness. Potential bias from authors’ dual roles as evaluators and designers further questions the objectivity of the analysis.
